- Home
- ORKA vs COGT Comparison
ORKA vs COGT Comparison
Compare ORKA & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- COGT
- Stock Information
- Founded
- ORKA 2004
- COGT 2014
- Country
- ORKA United States
- COGT United States
- Employees
- ORKA N/A
- COGT N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- COGT Health Care
- Exchange
- ORKA Nasdaq
- COGT Nasdaq
- Market Cap
- ORKA 1.0B
- COGT 984.0M
- IPO Year
- ORKA N/A
- COGT 2018
- Fundamental
- Price
- ORKA $24.04
- COGT $8.90
- Analyst Decision
- ORKA Strong Buy
- COGT Buy
- Analyst Count
- ORKA 6
- COGT 6
- Target Price
- ORKA $43.60
- COGT $14.67
- AVG Volume (30 Days)
- ORKA 139.3K
- COGT 1.3M
- Earning Date
- ORKA 11-13-2024
- COGT 11-12-2024
- Dividend Yield
- ORKA N/A
- COGT N/A
- EPS Growth
- ORKA N/A
- COGT N/A
- EPS
- ORKA N/A
- COGT N/A
- Revenue
- ORKA N/A
- COGT N/A
- Revenue This Year
- ORKA N/A
- COGT N/A
- Revenue Next Year
- ORKA N/A
- COGT N/A
- P/E Ratio
- ORKA N/A
- COGT N/A
- Revenue Growth
- ORKA N/A
- COGT N/A
- 52 Week Low
- ORKA $18.72
- COGT $3.67
- 52 Week High
- ORKA $53.88
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- COGT 28.97
- Support Level
- ORKA N/A
- COGT $9.97
- Resistance Level
- ORKA N/A
- COGT $11.16
- Average True Range (ATR)
- ORKA 0.00
- COGT 0.78
- MACD
- ORKA 0.00
- COGT -0.25
- Stochastic Oscillator
- ORKA 0.00
- COGT 2.02
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.